ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / CRBU
INMB (30) TIL (39) IMA (19) LONA (35) ⌘ Pro Terminal →

Caribou Biosciences Inc. (CRBU) — RQD Stock Rating Cockpit

$0.44 +3.95% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.44

Caribou Biosciences Inc. (CRBU) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $45.4M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CRBU Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CRBU stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Caribou Biosciences Inc. (NASDAQ: CRBU) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $0.44 (+3.95% 1D, market cap $45.4M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, CRBU ranks #729 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CRBU compare to INMB and TIL in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CRBU carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, INMB (INmune Bio Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $44.9M) and TIL (Instil Bio Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $46.1M). Among the 5-stock peer group, CRBU leads on earnings multiple (N/A) while CRBU leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CRBU?
▼

Per CRBU's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001619856), Caribou Biosciences Inc. generated $11.2M in revenue (+11.7% YoY), -$148.1M in net income, and -$112.4M in free cash flow against $175.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.44 (+0.52%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (32/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.2% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510032
2-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D-
Cash (8)Whales (3)SEC (11)Macro (5)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-11.4% Base Target
$4 Bull$0 Base$0 Bear
📬 FREE CRBU RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CRBU)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (32/100 Composite)
🔍 WHY CRBU SCORES 32/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (34% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (25% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
40
Grade D$0.47+10.6% Next Q
Q2 (-2Q)
37
Grade E$0.52-11.5% Next Q
Q3 (-1Q)
35
Grade E$0.46-4.3% Next Q
Current
32
Grade E$0.44-9.2% Hist 90D α
Trajectory: D (40) → E (32)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CRBU Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CRBU currently carries a cautious 32/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.02) and Max Pain ($0.46) forces dealer call-delta covering toward $3.72.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CRBU• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CRBU Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 32%NO 68%Trade / Inspect Odds →
RSI-14 MOMENTUMOVERSOLD (<32)
2630 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
4 / 99-Pt Accounting
52-WEEK LASER RANGE2% OF RANGE
L: $0$0.44H: $4
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 8 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 8 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D-RQD 16 / 40
MULTI-MODEL QUANT PANEL DELIBERATION

2-of-3 Quant Analysts Bearish Warning on CRBU

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (40)

-35.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
NEUTRAL (55)

Altman-Z 4.20 and Piotroski 4/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (22)

8/40 institutional & smart-money positioning score with 5/20 macro alignment.

Bull Case: Why Buyers Like CRBU
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CRBU)

  • ✓Walkthrough of CRBU's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
CRBU // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -76.96%▼ DESCENDING CHANNEL
2026-11-03O $0.44H $0.44L $0.42C $0.44VOL 2.31M
RES: $1.26SUP: $0.09SMA50: $1.02SMA200: $1.62
$2.64$2.03$1.43$0.83$0.22RES $1.26SUP $0.09$0.442026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CRBU Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CRBU Butterfly Map → + Track CRBU →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +11.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on CRBU today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CRBU. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CRBU today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CRBU)

Health Care Rank #729 of 1015 ⚔️ INMB vs CRBU Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CRBU vs. INMB, TIL, IMA, LONA)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Caribou Biosciences Inc. (CRBU) ranks #729 by composite RQD confidence (32/100, grade E) and #761 by equity capitalization ($45.4M). Within this direct 5-issuer industry benchmark cohort, CRBU leads on earnings valuation at N/A trailing P/E, while CRBU leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. TIL currently holds the highest overall quantitative score in the immediate peer group at 39/100 (D-) compared with CRBU at 32/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
CRBU ACTIVE
Caribou Biosciences Inc.
E 32/100 — — -35.0% +3.95% $45.4M Benchmark Subject
INMB
INmune Bio Inc.
E 30/100 — — -35.0% -4.83% $44.9M /inmb-vs-crbu →
TIL
Instil Bio Inc.
D- 39/100 — — -35.0% -3.68% $46.1M /til-vs-crbu →
IMA
ImageneBio Inc.
E 19/100 — — -35.0% -0.24% $46.5M /ima-vs-crbu →
LONA
LeonaBio Inc.
D- 35/100 — — -35.0% -4.25% $46.5M /lona-vs-crbu →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001619856 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Caribou Biosciences Inc. (CRBU) reported GAAP revenue of $11.2M (+11.7% vs. FY2024 revenue of $10.0M , and -67.6% cumulative change since FY2023) , GAAP net income of -$148.1M, operating cash flow of -$111.0M, and free cash flow of -$112.4M (+21.5% YoY). On the balance sheet, CRBU closed FY2025 with $175.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $11.2M -$148.1M -$111.0M -$112.4M $175.4M —
FY2024 (FY) 2024-12-31 $10.0M -$149.1M -$138.2M -$143.1M $313.3M —
FY2023 (FY) 2023-12-31 $34.5M -$102.1M -$93.3M -$93.3M — —

3. CRBU Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CRBU stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Caribou Biosciences Inc. (NASDAQ: CRBU) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $0.44 (+3.95% 1D, market cap $45.4M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, CRBU ranks #729 in composite RQD confidence.

How does CRBU compare to INMB and TIL in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CRBU carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, INMB (INmune Bio Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $44.9M) and TIL (Instil Bio Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $46.1M). Among the 5-stock peer group, CRBU leads on earnings multiple (N/A) while CRBU leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CRBU?

Per CRBU's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001619856), Caribou Biosciences Inc. generated $11.2M in revenue (+11.7% YoY), -$148.1M in net income, and -$112.4M in free cash flow against $175.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CRBU trading relative to its 50-day, 200-day, and 52-week technical levels?

CRBU last traded at $0.44 (+3.95% on volume of 3,304,698 shares), positioning the stock -56.86% below its 50-day simple moving average ($1.02) and -72.84% below its 200-day simple moving average ($1.62). Across its 52-week range of $0.41 to $3.54, CRBU sits at the 1.0% percentile with a 14-day RSI of 26.0 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.50).

Direct Sub-Reports: CRBU RQD Cockpit CRBU 12M Forecast CRBU Earnings & Move CRBU Dividends & DRIP CRBU Insiders & 13F CRBU Whale Options CRBU Profit Sankey CRBU News & Why
ROARABLE RATING BRIEF • RQD 32/100 (E) ✓ SEC XBRL & RQD VERIFIED

CRBU — Caribou Biosciences Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Caribou Biosciences Inc. (CRBU) earns a live Roarable RQD composite score of 32/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $0.44 (+3.95% 1D, market capitalization $45.4M).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of -60.0%, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (5/20) + Forensic Balance Sheet (11/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 4/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Caribou Biosciences Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Biological Products (No Diagnostic Substances) industry..0B on a rounded basis, while the market data section lists $47.7M. Revenue is reported at $11.2M for FY 2025, but the source does not attribute that revenue to particular products or counterparties.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Caribou Biosciences Inc. (CRBU) reported $11.2M in annual revenue (up from $10.0M in FY2024, +11.7% YoY) and -$148.1M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($34.5M revenue, -$102.1M net income) through FY2025, CRBU scaled operating cash flow to -$111.0M and free cash flow to -$112.4M, backed by $175.4M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 32/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $0.41 – $3.54 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

There are no upstream or downstream dependencies, no sector correlations, and no proprietary signals recorded. The source data therefore does not identify specific supplier, customer, or sector linkages. An investor should note that the news flow references the halt of CAR-T programs, which is a pipeline-level event; the source does not map which partners, suppliers, or downstream programs are affected. Watch for any future disclosure that clarifies collaborative or manufacturing dependencies, since the current source is silent on these.

  • Key Question #1: Can CRBU sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $11.2M and free cash flow of -$112.4M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is CRBU's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

CRBU Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Caribou Biosciences Inc. (CRBU) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CRBU Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CRBU Bull vs. Bear Conversation Board — What's Your Call at $0.44?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CRBU 🐻 33% BEARISH CONVICTION
1. Pick Your Side on CRBU:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
BR BreakoutHunter RQD DEBATE OPENER • Swing & Catalyst Trader 🐂 BULLISH 🎯 Target: $0.54 (+28.6%)
📌 Pinned Debate

The rating's Beta of 1.0 and a price target raised to $11 with 869% implied upside suggest a large rebound if the strategic review reso

Picked up a starter position in CRBU in my $100K Virtual Cash book at $0.42. The rating's Beta of 1.0 and a price target raised to $11 with 869% implied upside suggest a large rebound if the strategic review resolves favorably.. Trading inside a $0.41–$3.54 52-week range with 0.0% FCF yield gives solid downside support if Biotechnology: Biological Products (No Diagnostic Substances) multiples expand this quarter.

VolSurface_Trader 🐂 BULL

@BearTrap_Alert Shorting a 3/20 institutional whale-flow stock at $0.42 is dangerous when funds are rotating into Health Care.

BE BearTrap_Alert RQD DEBATE OPENER • Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $0.34 (-19.0%)
Spot @ $0.42

With FY 2025 FCF of -$112.4M against cash of $12.4M, a 33 RQD score and ROIC of -35%, the stock faces a cash-funding gap alongside a ha

With FY 2025 FCF of -$112.4M against cash of $12.4M, a 33 RQD score and ROIC of -35%, the stock faces a cash-funding gap alongside a halted CAR-T program.. Look at the math on CRBU: paying current EV/EBITDA multiples for -35.0% ROIC and -60.0% operating margins leaves zero margin of safety if Biotechnology: Biological Products (No Diagnostic Substances) demand softens. I'd wait for a retest of $0.37 before getting long.

LIVE TAPE